Sabrina A. Hogan
YOU?
Author Swipe
View article: EXTH-87. Bifunctional Phagocytic Synapse Enhancers for Cancer Immunotherapy
EXTH-87. Bifunctional Phagocytic Synapse Enhancers for Cancer Immunotherapy Open
Immunotherapy profoundly impacted cancer treatments by harnessing the patient’s immune system. Phagocytosis, the process whereby immune cells engulf and destroy foreign particles or cells, plays a critical role in tumour cell clearance. He…
View article: Bifunctional Phagocytic Synapse Enhancers for Cancer Immunotherapy
Bifunctional Phagocytic Synapse Enhancers for Cancer Immunotherapy Open
Immunotherapy profoundly impacted cancer treatments by harnessing the patient’s immune system. Phagocytosis, the process whereby immune cells engulf and destroy foreign particles or cells, plays a critical role in tumour cell clearance. He…
View article: Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker
Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker Open
A significant challenge for chimeric antigen receptor (CAR) T cell therapy against glioblastoma (GBM) is its immunosuppressive microenvironment, which is densely populated by protumoral glioma-associated microglia and macrophages (GAMs). M…
View article: Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse
Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse Open
Glioblastoma (GBM) is a lethal brain tumor without effective treatment options. This study aimed to characterize longitudinal tumor changes in order to find potentially actionable targets to prevent GBM relapse. We extracted RNA and protei…
View article: Supplementary Fig. S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Fig. S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Enlarged proteomaps results for the tumor cell lysate dataset.
View article: Supplementary Table S5 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S5 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Statistical analysis of baseline clinical parameters in the independent Zurich serum validation cohort A (n=80).
View article: Supplementary Table S5 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S5 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Statistical analysis of baseline clinical parameters in the independent Zurich serum validation cohort A (n=80).
View article: Supplementary Table S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Characteristics and clinical baseline parameters of melanoma patients in the study.
View article: Supplementary Fig. S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Fig. S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Primary melanoma tumor cells of NR display a distinctive immunophenotype.
View article: Supplementary Table S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Differentially expressed proteins (DEPs) in NR of the discovery serum and tumor cell cohorts.
View article: Supplementary Table S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Differentially expressed proteins (DEPs) in NR of the discovery serum and tumor cell cohorts.
View article: Supplementary Table S6 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S6 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Results of the Wilcoxon rank sum tests, dependent variable = first component of the PCA.
View article: Supplementary Fig. S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Fig. S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Enlarged proteomaps results for the tumor cell lysate dataset.
View article: Supplementary Table S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Antibodies used for immunofluorescence staining on a melanoma tissue microarray (TMA).
View article: Supplementary Fig. S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Fig. S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Differentially expressed proteins (DEPs) and functional annotation of NR proteomes based on GO term classification.
View article: Supplementary Fig. S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Fig. S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
TME of melanoma NR represents a potential target for therapy.
View article: Supplementary Table S6 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S6 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Results of the Wilcoxon rank sum tests, dependent variable = first component of the PCA.
View article: Data from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Data from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Purpose:Despite high clinical need, there are no biomarkers that accurately predict the response of patients with metastatic melanoma to anti-PD-1 therapy.Experimental Design:In this multicenter study, we applied protein depletion and enri…
View article: Supplementary Table S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Antibodies used for immunofluorescence staining on a melanoma tissue microarray (TMA).
View article: Supplementary Table S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Characteristics and clinical baseline parameters of melanoma patients in the study.
View article: Supplementary Fig. S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Fig. S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Primary melanoma tumor cells of NR display a distinctive immunophenotype.
View article: Supplementary Fig. S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Fig. S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Differentially expressed proteins (DEPs) and functional annotation of NR proteomes based on GO term classification.
View article: Supplementary Fig. S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Fig. S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
TME of melanoma NR represents a potential target for therapy.
View article: Supplementary Table S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Statistical analysis of baseline clinical parameters in the serum discovery cohort (n=56).
View article: Supplementary Table S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Supplementary Table S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Statistical analysis of baseline clinical parameters in the serum discovery cohort (n=56).
View article: Data from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Data from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy Open
Purpose:Despite high clinical need, there are no biomarkers that accurately predict the response of patients with metastatic melanoma to anti-PD-1 therapy.Experimental Design:In this multicenter study, we applied protein depletion and enri…
View article: Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation
Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation Open
Glioblastoma (GBM) harbors a highly immunosuppressive tumor microenvironment (TME) which influences glioma growth. Major efforts have been undertaken to describe the TME on a single-cell level. However, human data on regional differences w…
View article: Reviewer #2 (Public Review): Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation
Reviewer #2 (Public Review): Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation Open
Glioblastoma (GBM) harbors a highly immunosuppressive tumor microenvironment (TME) which influences glioma growth. Major efforts have been undertaken to describe the TME on a single-cell level. However, human data on regional differences w…
View article: Author Response: Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation
Author Response: Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation Open
Glioblastoma (GBM) harbors a highly immunosuppressive tumor microenvironment (TME) which influences glioma growth. Major efforts have been undertaken to describe the TME on a single-cell level. However, human data on regional differences w…
View article: Reviewer #1 (Public Review): Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation
Reviewer #1 (Public Review): Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation Open
Glioblastoma (GBM) harbors a highly immunosuppressive tumor microenvironment (TME) which influences glioma growth. Major efforts have been undertaken to describe the TME on a single-cell level. However, human data on regional differences w…